Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE III: Enzalutamide vs Enzalutamide + Ra223 in mCRPC with Bone Metastases
2023-510453-41-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial in castration-resistant prostate cancer (CRPC) comparing Enzalutamide monotherapy with Enzalutamide + radium Ra 223 (2 arms). Primary endpoint: Radiological progression-free survival (rPFS1). Planned start Jul 2024; status: authorised.
02
Drugs
enzalutamideradium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-510453-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510453-41-00.